Obesity and obstructive sleep apnea syndrome

Journal of Otolaryngology - Head and Neck Surgery

Volumn 39, Issue 6, 2010, Pages 744-751

  Acioǧlu, Engin ^a   Yiǧit, Özgür ^a   Sunter, A Volkan ^a   Taşkin, Ümit ^a   Inal, Berrin Berçik ^a   Şahin, Mustafa ^a  

^a ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Insulin resistance; Obesity; Visfatin

Indexed keywords

FATTY ACID BINDING PROTEIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BODY MASS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPOXEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SLEEP APNEA SYNDROME;

ADULT; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; SLEEP APNEA, OBSTRUCTIVE;

EID: 78650205648     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2010.090320     Document Type: Article

References (42)

1. Douglas NJ, Polo O. Pathogenesis of obstructive sleep apnoea/hypopnoea syndrome. Lancet 1994;344:653-5. (Pubitemid 24274312)
2. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;29:1230-5.
3. Rajala R, Partinen M, Sane T, et al. Obstructive sleep apnea syndrome in morbidly obese patients. J Intern Med 1991;230:125-9.
4. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001;14:103S-15S.
5. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005;56:45-62.
6. Ferroni P, Basili S, Falco A, et al. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6:424-31.
7. Fantuzzi G. J. Adipose tissue, adipokines, and inflammation. Allergy Clin Immunol 2005;115:911-9.
8. Pack AI. Advances in sleep-disordered breathing. Am J Respir Crit Care Med 2006;173:7-15.
9. American Diabetes Association Consensus Development Conference on Insulin Resistance, 5-6 November 1997. Diabetes Care 1998;21:310-4.
10. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.
11. Ip MSM, Lam B, Ng MMT, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670-6.
12. Punjabi NM, Beamer BA. C-reactive protein is associated with sleep disordered breathing independent of obesity. Sleep 2007;30:29-34.
13. Stoohs RA, Facchini F, Guilleminault C. Insulin resistance and sleep-disordered breathing in healthy humans. Am J Respir Crit Care Med 1996;154:170-4. (Pubitemid 26255785)
14. Chung S, Yoon IY, Shin YK, et al. Endothelial dysfunction and C-reactive protein in relation with the severity of obstructive sleep apnea. Sleep 2007;30:997-1001.
15. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105:1243-52.
16. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;22:763-70.
17. Phillips BG, Kato M, Narkiewicz K, et al. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000;279:H234-7.
18. Chin K, Shimizu K, Nakamura T, et al. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999;100:706-12.
19. Ip MS, Lam KS, Ho C, et al. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000;118:580-6.
20. Harsch IA, Konturek PC, Koebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnea: effect of CPAP treatment. Eur Respir J 2003;22:251-7.
21. Barceló A, Barbé F, Llompart E, et al. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med 2005;171:183-7.
22. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1998;1391:287-306.
23. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000;11:175-80.
24. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 2002;59:1096-116.
25. Chmurzyńska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 2006;47:39-48.
26. Tan NS, Shaw NS, Vinckenbosch N, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 2002;22:5114-27.
27. Haunerland NH, Spener F. Fatty acid-binding proteins - insights from genetic manipulations. Prog Lipid Res 2004;43:328-49.
28. Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism 2007;56:1735-41.
29. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-13.
30. Makowski L, Hotamisligil GS. Fatty acid binding proteins - the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004;134:2464S-8S.
31. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002;13:141-7.
32. Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537-43.
33. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
34. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
35. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
36. Trakada G, Steiropoulos P, Nena E, et al. Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome. Sleep Breath 2009;13:349-55.
37. Sharma SK, Kumpawat S, Coel A, et al. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep disordered breathing. Sleep Med 2007;8:12-17.
38. Kaditis A, Alexopoulos E, Damani E, et al. Obstructive sleep-disordered breathing and fasting insulin levels in nonobese children. Pediatr Pulmonol 2005;40:515-23.
39. Tauman R, O'Brien L, Ivanenko A, et al. Obesity rather than sleep-disordered breathing as the major determinant of insulin resistance and altered lipidemia in snoring children. Pediatrics 2005;116:e66-73.
40. Kapsimalis F, Varouchakis G, Manousaki A, et al. Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. Lung 2008;186:209-17.
41. Onat A, Hergenç G, Yüksel H, et al. Neck circumference as a measure of central obesity: associations with metabolic syndrome and obstructive sleep apnea syndrome beyond waist circumference. Clin Nutr 2009;28:46-51.
42. Coughlin SR, Mawdsley L, Mugarza JA, et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004;25:735-41.